China National Medical Products Administration approves Truvada for HIV pre-exposure prophylaxis

Gilead

11 August 2020 - Truvada is the first HIV PrEP medicine approved in China.

Gilead Sciences today announced that the China National Medical Products Administration has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. 

Truvada for PrEP should be taken once daily and used together with safer sex practices. Individuals must have a negative HIV-1 test immediately prior to initiating Truvada for PrEP.

Read Gilead Sciences press release

Michael Wonder

Posted by:

Michael Wonder